Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CDR 132L

Next Previous
Drug Profile

CDR 132L

Alternative Names: CDR-132L; NN-6706

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hannover Medical School
  • Developer Cardior Pharmaceuticals
  • Class Antisense oligonucleotides; Heart failure therapies; Oligonucleotides
  • Mechanism of Action MIRN132 microRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart failure

Most Recent Events

  • 19 May 2025 Novo Nordisk plans a phase II trial for Heart failure in the US, Canada, Germany, India, Japan, South Korea, Poland, Spain and United Kingdom (IV) (NCT06979362)
  • 19 May 2025 Novo Nordisk plans a phase II 8282-Reduced trial for Heart Failure in Australia, Czech, South Korea, Germany, India, Japan, South Korea, Netherlands, Poland, Spain, the UK (IV, Infusion) (NCT06979375)
  • 05 Jun 2024 Cardior Pharmaceuticals withdraws a phase II REMOD-REVERT trial in Heart failure and Cardiomegaly (IV) due to transfer of study responsibility and planning (NCT05953831)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top